Contact Us
Drug Search Results
More Filters [+]

Seliciclib

Alternative Names: seliciclib, roscovitine, r-roscovitine, al-39256
Latest Update: 2024-04-30
Latest Update Note: News Article

Product Description

Mechanisms of Action: CDK9 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Ophthalmic

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Cyclacel
Company Location: BERKELEY HEIGHTS NJ 07922
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Seliciclib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Non-Small-Cell Lung Cancer|ACTH-Secreting Pituitary Adenoma|Pituitary ACTH Hypersecretion|Cystic Fibrosis|Glaucoma, Open-Angle|Hypertension

Phase 1: Oncology Solid Tumor Unspecified|Triple Negative Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
Pro52406

P2

Recruiting

ACTH-Secreting Pituitary Adenoma|Pituitary ACTH Hypersecretion

2025-08-01

CYC682-07

P1

Completed

Oncology Solid Tumor Unspecified

2019-07-16

44%
Pro35720

P2

Terminated

ACTH-Secreting Pituitary Adenoma|Pituitary ACTH Hypersecretion

2018-10-01

ROSCO-CF

P2

Terminated

Cystic Fibrosis

2018-07-26

Recent News Events

Date

Type

Title

04/30/2024

PubMed

 An E7-retinoblastoma protein pathway mechanism may account for the higher carcinogenic ability of HPV16 over HPV58 in cervical cancer.

04/30/2024

PubMed

 Molecular docking approach for the design and synthesis of new pyrazolopyrimidine analogs of roscovitine as potential CDK2 inhibitors endowed with pronounced anticancer activity.

04/30/2024

News Article

 $8 Million Private Placement Announcement Sends Biotech Flying

04/01/2024

PubMed

 α-synuclein regulates Cyclin D1 to promote abnormal initiation of the cell cycle and induce apoptosis in dopamine neurons.

04/21/2020

News Article

 Organizations Begin Testing Treatments to Mitigate the Viral Threat

04/20/2020

News Article

 Cyclacel Pharmaceuticals Announces Collaboration With the University of Edinburgh to Study Its CDK Inhibitors to Reduce Runaway Inflammation in COVID-19 Disease

01/13/2020

News Article

 Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions